Spots Global Cancer Trial Database for hypopharynx
Every month we try and update this database with for hypopharynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | NCT01066741 | Oropharynx Canc... Hypopharynx Can... | Homeodent® 1.4% Sodium Bic... | 18 Years - 85 Years | Centre Leon Berard | |
| Pembrolizumab in Combination With CRT for LA-SCCHN | NCT02586207 | Head and Neck C... Squamous Cell C... Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer Laryngeal Cance... | pembrolizumab (... Cisplatin Radiation | 18 Years - | Sanford Health | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer | NCT00094081 | Head and Neck N... | tirapazamine (S... cisplatin Radiation Thera... | 18 Years - | Sanofi | |
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures | NCT02262247 | OSA Oral Disease Oropharyngeal N... Hypopharyngeal ... | 22 Years - | Medrobotics Corporation | ||
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer | NCT02892487 | Cancer of Head ... | Swallowing ther... | 18 Years - | Rennes University Hospital | |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer | NCT01089803 | Squamous Cell C... Laryngeal Cance... | 18 Years - | University of Minnesota | ||
| Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN | NCT01884259 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Docetaxel Cisplatin 5-fluorouracil Cetuximab Induc... Cetuximab Radio... Boost irradiati... | 18 Years - 75 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT01427205 | Head and Neck C... | Cetuximab OSI-906 Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| The Head and Neck Tumor Biobank | NCT01644786 | Head and Neck S... | 18 Years - | Maastricht Radiation Oncology | ||
| Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer | NCT01326923 | Head and Neck S... | Cetuximab | 18 Years - | Louisiana State University Health Sciences Center Shreveport | |
| Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | NCT00101582 | Mucositis Solid Tumors Stomatitis Head and Neck C... Squamous Cell C... | Placebo palifermin cisplatin chemo... Radiotherapy | 18 Years - | Swedish Orphan Biovitrum | |
| Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck | NCT01287390 | Primary Non-ope... Primary Non-ope... Primary Non-ope... Primary Non-ope... | video fluorosco... extra imaging scoring acute t... scoring of late... scoring quality... | 18 Years - | University Hospital, Ghent | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer | NCT02892487 | Cancer of Head ... | Swallowing ther... | 18 Years - | Rennes University Hospital | |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer | NCT00094081 | Head and Neck N... | tirapazamine (S... cisplatin Radiation Thera... | 18 Years - | Sanofi | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer | NCT01647477 | Upper Aerodiges... | interview questionnaires | 18 Years - | Centre Oscar Lambret | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | NCT01066741 | Oropharynx Canc... Hypopharynx Can... | Homeodent® 1.4% Sodium Bic... | 18 Years - 85 Years | Centre Leon Berard | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer | NCT01089803 | Squamous Cell C... Laryngeal Cance... | 18 Years - | University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
